Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CoAxia’s NeuroFlo Catheter For Stroke Shot Down By Panel

This article was originally published in The Gray Sheet

Executive Summary

FDA’s Neurological Devices panel found that the benefits of the catheter system do not outweigh the risks for the intended expanded use to treat acute ischemic stroke, and that further studies are needed.


Related Content

Zoll Acquires CoAxia Assets In Bid To Revive NeuroFlo Stroke Catheter
CoAxia On Last Legs Following Contested FDA Panel Meeting
Regulatory News In Brief
FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts